Gene therapy deal to drive “pipeline transformation” for Axovant Sciences, says Oppenheimer
Axovant expects to initiate a study of AXO-Lenti-PD in patients with advanced Parkinson's disease by the end of 2018
Company
Oxford BioMedica PLC
LON:OXB
Oxford BioMedica is a biopharmaceutical company specialising in the development and commercialisation of innovative gene-based medicines. The Company was established in 1995 as a spin out from Oxford University, and is listed on the London Stock Exchange. Oxford BioMedica's products use genes as the mediators of a therapeutic effect and/or immune response. The company has a platform of gene delivery technologies, which are predominately based on highly engineered viral systems. Oxford BioMedica has core expertise in gene delivery, as well as in-house clinical, regulatory and manufacturing know-how.
69 stories · page 3 of 4
PowerHouse Energy shares lifted as it debunks speculation on Science Park closure
A look at some of the biggest risers and fallers in London on Wednesday
Oxford BioMedica shares jump as it enters licensing agreement for Parkinson’s treatment
The gene and cell therapy group said under the agreement with Axovant Sciences it would receive a US$30mln upfront payment
Archive
Momentum investing: Use the Force, Luke
A lot of academic research suggests a momentum investing strategy outperforms the market. John Harrington attempts to concoct a lazy person's momentum investing system.
Oxford BioMedica’s shares shares rise after unveiling US$100mln agreement with Bioverativ
Oxford BioMedica will receive a US$5mln payment upfront and will be eligible to receive various milestone payments potentially worth in excess of US$100mln
FTSE 100 closes in the red but gold price boosts miners
The FTSE 100 closed down 45 at 7,387, while the FTSE 250 lost 86 at 19,773.
What’s in store for Kingfisher investors on Thursday?
The B&Q owner's French business has overshadowed recent decent performances, will it blight the next figures?
Archive
UK economic health eyed from inflation, jobless numbers; Kingfisher updates on trading
Week ahead includes UK inflation, unemployment, average earnings data; trading update from Kingflsher PLC, interims from Hargreaves Lansdown PLC, Admiral PLC ...
Oxford Biomedica extends contract with Swiss pharma giant Novartis
Oxford Biomedica said a new contract with Novartis could generate more than US$100mln over the next three years
Archive
Fed fall-out, Dutch elections and Sainsbury's sales to provide food for thought
A rise is taken as read, and – assuming the Fed does not perform a triple Salchow with accompanying back-flip – the focus will be on the Fed’s commentary in its post-meeting statement.
Oxford Biomedica lauds “encouraging” trial results from a Phase I/II cancer trial involving its TroVax immunotherapy product
The firm said the results showed patients given TroVax and low dose cyclophosphamide demonstrated “significant anti-5T4 immune responses”
Risers and fallers: Nyota, Conroy Gold, Centamin, Ascent Resources, Shanta Gold, Legendary Investments
Main share price risers and fallers in London at 3.45pm
PREVIEW; GameAccount Network needs more landmark deals
Other companies reporting include Lloyds Banking, Taylor Wimpey and WPP
FTSE 100 hits new high for 2016 after late surge
The Footsie put on a late spurt to finish in the blue, as US stocks roused themselves after a sluggish start.
London shares fall as Kuwaiti oil workers end strike
Shares dropped as crude prices fell, but Stagecoach provided interest
Market gains silver lining as precious metals twinkle
Silver prices hit a 10-month high and gold stocks glittered
Sainsbury interest in Home Retail buoys London shares
Sainsbury's approached Home Retail in November about cash-and-share deal